Yishi Wu

Dr. Yishi Wu

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
XZXi-Wen Zhang
Xi-Wen Zhang
YWYishi Wu
Yishi Wu
TXTianmin Xu
Tianmin Xu
MCmanhua cui
manhua cui
Ovarian cancer (OC) is among the most common gynecologic malignancies with a poor prognosis and a high mortality rate. Most patients are diagnosed at an advanced stage (stage III or IV), with 5-year survival rates ranging from 25% to 47% worldwide. Surgical resection and first-line chemotherapy are the main treatment modalities for OC. However, patients usually relapse within a few years of initial treatment due to resistance to chemotherapy. Cell-based therapies, particularly adoptive T-cell therapy and chimeric antigen receptor T (CAR-T) cell therapy, represent an alternative immunotherapy approach with great potential for hematologic malignancies. However, the use of CAR-T-cell therapy for the treatment of OC is still associated with several difficulties. In this review, we comprehensively discuss recent innovations in CAR-T-cell engineering to improve clinical efficacy, as well as strategies to overcome the limitations of CAR-T-cell therapy in OC.

1 October 2025 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
RZRuimin Zhao
Ruimin Zhao
ZLZongyu Liu
Zongyu Liu
LFLimei Fan
Limei Fan
MFMiaomiao Fu
Miaomiao Fu
YWYishi Wu
Yishi Wu
Nanotechnology platforms facilitate therapeutic drug delivery and offer various advantages over conventional drugs, such as biocompatibility, non-inflammatory effects, high therapeutic output, biodegradability, non-toxicity, and biocompatibility. Due to the inherent drawbacks of conventional drug delivery to cancerous tissues, nanotechnology-based alternatives have been developed for such diseases. Gynecologic malignant tumors (GCs), include various types of cervical, endometrial, and ovarian cancers. The epidemiological characteristics of the tumors show that their incidence is increasing significantly and tends to be younger, which is a serious threat to women’s physical and mental health. This article provides a systematic review of the latest research results on nanomaterials in the diagnosis and treatment of gynecological malignancies, including 2 sections on nanomaterials-based diagnostic and therapeutic strategies in gynecological cancers. In particular, the article also analyzes the challenges faced by nanotechnology, including toxicity, technology, and clinical translation issues. These applications not only improve the therapeutic efficacy of gynecological cancers, but also reduce the toxicity and side effects, and provide a new direction for the precise treatment of gynecological cancers.